CA AB1860

Extends the prohibition on excessive copayments for orally administered anticancer medications until January 1, 2024 (previously set to expire January 1, 2019)

Increases the maximum copayment and coinsurance limit from $200 to $250 for a 30-day supply of a prescribed orally administered anticancer medication

Removes the authorization for health care service plans to adjust the copayment limit annually based on Consumer Price Index increases

Applies to both health care service plans under the Knox-Keene Act and health insurance policies issued, amended, or renewed on or after January 1, 2015

Exempts Medicare coverage and high deductible health plans until deductibles are met from the copayment cap requirements